219 results on '"Mukae, H."'
Search Results
2. Exacerbationof Pneumococcal Pneumonia in Triply Nitric Oxide Synthase Knockout Mice
- Author
-
Ashizawa, H., primary, Iwanaga, N., additional, Ito, Y., additional, Hirayama, T., additional, Yoshida, M., additional, Takeda, K., additional, Ide, S., additional, Takazono, T., additional, Izumikawa, K., additional, Yanagihara, K., additional, Tsutsui, M., additional, and Mukae, H., additional
- Published
- 2024
- Full Text
- View/download PDF
3. Effect of Lactococcus Lactis Strain Plasma on T-cell Immune Response in Patients With Omicron COVID-19
- Author
-
Arakaki, W., primary, Yamamoto, K., additional, Inoue, T., additional, Iwanaga, N., additional, Morinaga, Y., additional, Izumikawa, K., additional, Yanagihara, K., additional, and Mukae, H., additional
- Published
- 2024
- Full Text
- View/download PDF
4. First clinical evaluation of the QIAreachTM QuantiFERON-TB for tuberculosis infection and active pulmonary disease
- Author
-
Fukushima, K., Akagi, K., Kondo, A., Kubo, T., Sakamoto, N., and Mukae, H.
- Published
- 2022
- Full Text
- View/download PDF
5. Human vγ2vδ2 T Cells Attenuate Collagen Type I Expression in Lung Fibroblasts By Inhibiting Myocardin Expression
- Author
-
Okuno, D., primary, Sakamoto, N., additional, Tokito, T., additional, Yura, H., additional, Kido, T., additional, Ishimoto, H., additional, Ishimatsu, Y., additional, Tanaka, Y., additional, and Mukae, H., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Bacterial Coinfections in COVID-19 Patients With Acute Respiratory Failure: Japan National Registry Survey
- Author
-
Yamamoto, K., primary, Akiyama, T., additional, Matsunaga, N., additional, Tsuzuki, S., additional, Asai, Y., additional, Tanaka, Y., additional, Iwanaga, N., additional, Tashiro, M., additional, Izumikawa, K., additional, Yanagihara, K., additional, Ohmagari, N., additional, and Mukae, H., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Effects of Administering Intravenous Azithromycin Within 7 Days of Hospitalization on Influenza Virus Pneumonia Complicated With Acute Respiratory Distress Syndrome: A Propensity Score Analysis Using a Nationwide Administrative Database
- Author
-
Tokito, T., primary, Kido, T., additional, Muramatsu, K., additional, Tokutsu, K., additional, Okuno, D., additional, Yura, H., additional, Ishimoto, H., additional, Takazono, T., additional, Sakamoto, N., additional, Obase, Y., additional, Ishimatsu, Y., additional, Fujino, Y., additional, Yatera, K., additional, Fushimi, K., additional, Matsuda, S., additional, and Mukae, H., additional
- Published
- 2023
- Full Text
- View/download PDF
8. Suppression by Clarithromycin of IL-8 Production From Human Airway Epithelial Cells Treated With Prevotella Intermedia Supernatants
- Author
-
Iwanaga, N., primary, Ashizawa, H., additional, Ito, Y., additional, Ashizawa, N., additional, Hirayama, T., additional, Takeda, K., additional, Ide, S., additional, Takazono, T., additional, Naito, M., additional, Tanaka, Y., additional, Izumikawa, K., additional, Yanagihara, K., additional, and Mukae, H., additional
- Published
- 2023
- Full Text
- View/download PDF
9. Exacerbation of Oral Streptococci-induced Pneumonia by Prevotella Intermedia Depends on the Type IX Secretion System
- Author
-
Ashizawa, H., primary, Iwanaga, N., additional, Ito, Y., additional, Ashizawa, N., additional, Hirayama, T., additional, Takeda, K., additional, Ide, S., additional, Takazono, T., additional, Naito, M., additional, Tanaka, Y., additional, Izumikawa, K., additional, Yanagihara, K., additional, and Mukae, H., additional
- Published
- 2023
- Full Text
- View/download PDF
10. 58: SARS-COV-2 ANTIBODY CHARACTERISTICS OF SALIVA FROM VACCINATED INDIVIDUALS
- Author
-
Ota, K., primary, Mitsumoto-Kaseida, F., additional, Sakamoto, K., additional, Kosai, K., additional, Hasegawa, H., additional, Yamamoto, K., additional, Izumikawa, K., additional, Mukae, H., additional, Kohno, S., additional, and Yanagihara, K., additional
- Published
- 2022
- Full Text
- View/download PDF
11. 316P Phase II study of ramucirumab and docetaxel for platinum-resistance NSCLC patients with malignant pleural effusion: Analysis of pleural effusion control rate
- Author
-
Ogata, R., primary, Takemoto, S., additional, Fukuda, M., additional, Senju, H., additional, Nakatomi, K., additional, Sugasaki, N., additional, Tomono, H., additional, Suyama, T., additional, Shimada, M., additional, Akagi, K., additional, Hayashi, F., additional, Dotsu, Y., additional, Taniguchi, H., additional, Gyotoku, H., additional, Yamaguchi, H., additional, Nagashima, S., additional, Soda, H., additional, Kinoshita, A., additional, and Mukae, H., additional
- Published
- 2022
- Full Text
- View/download PDF
12. EP08.01-064 Serum NY-ESO-1 and XAGE1 Antibodies Predict and Monitor Clinical Responses to Immune Checkpoint Therapy for NSCLC
- Author
-
Oka, M., primary, Kurose, K., additional, Sakaeda, K., additional, Fukuda, M., additional, Sakai, Y., additional, Atarashi, Y., additional, Shimizu, K., additional, Masuda, T., additional, Nakatomi, K., additional, Kawase, S., additional, Suetsugu, T., additional, Mizuno, K., additional, Takemoto, S., additional, Yamaguchi, H., additional, Inoue, H., additional, Hattori, N., additional, Nakata, M., additional, Mukae, H., additional, and Oga, T., additional
- Published
- 2022
- Full Text
- View/download PDF
13. EP08.04-005 Phase II Study of Ramucirumab and Docetaxel for NSCLC Patients with Malignant Pleural Effusion
- Author
-
Takemoto, S., primary, Fukuda, M., additional, Senju, H., additional, Nakatomi, K., additional, Sugasaki, N., additional, Ogata, R., additional, Tomono, H., additional, Suyama, T., additional, Shimada, M., additional, Akagi, K., additional, Hayashi, F., additional, Gyotoku, H., additional, Yamaguchi, H., additional, Nagashima, S., additional, Soda, H., additional, Kinoshita, A., additional, and Mukae, H., additional
- Published
- 2022
- Full Text
- View/download PDF
14. A National Survey of Noninvasive Modalities in the Management of COVID-19 Patients with Acute Respiratory Failure - Results from the COVIREGI-JP Database
- Author
-
Yamamoto, K., primary, Tomii, K., additional, Izumi, S., additional, Ishimoto, H., additional, Takazono, T., additional, Iwanaga, N., additional, Ashizawa, N., additional, Takemoto, S., additional, Obase, Y., additional, Tashiro, M., additional, Tanaka, T., additional, Yamauchi, M., additional, Hosogaya, N., additional, Izumikawa, K., additional, Yanagihara, K., additional, and Mukae, H., additional
- Published
- 2022
- Full Text
- View/download PDF
15. Evaluation of QFT-Plus performance using blood samples stored at room temperature
- Author
-
Fukushima, K., primary, Akagi, K., additional, Kondoh, A., additional, Kubo, T., additional, Ito, Y., additional, Oda, Y., additional, Nagihara, Y., additional, Sakamoto, N., additional, and Mukae, H., additional
- Published
- 2021
- Full Text
- View/download PDF
16. Comparison of the Effectiveness of Baloxavir and Oseltamivir in Outpatients With Influenza B.
- Author
-
Takazono T, Ito G, Hosogaya N, Iwanaga N, Komeda T, Kobayashi M, Kitanishi Y, Ogura E, and Mukae H
- Subjects
- Humans, Male, Retrospective Studies, Female, Middle Aged, Adult, Aged, Young Adult, Adolescent, Hospitalization statistics & numerical data, Child, Pyridines therapeutic use, Japan epidemiology, Child, Preschool, Treatment Outcome, Infant, Aged, 80 and over, Influenza, Human drug therapy, Dibenzothiepins therapeutic use, Oseltamivir therapeutic use, Antiviral Agents therapeutic use, Pyridones therapeutic use, Morpholines therapeutic use, Triazines therapeutic use, Outpatients, Influenza B virus drug effects
- Abstract
This retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (n = 4822) for preventing severe events compared with oseltamivir (n = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2-14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti-influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13-5.43). Pneumonia and additional anti-influenza therapy were also less frequent with baloxavir, thus supporting its use. Trial Registration: UMIN Clinical Trials Registry Study ID: UMIN000051382., (© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
17. Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial.
- Author
-
Yotsuyanagi H, Ohmagari N, Doi Y, Yamato M, Fukushi A, Imamura T, Sakaguchi H, Sonoyama T, Sanaki T, Ichihashi G, Tsuge Y, Uehara T, and Mukae H
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Antiviral Agents therapeutic use, Double-Blind Method, Indazoles, Treatment Outcome, Triazines, Triazoles, COVID-19 Drug Treatment, Post-Acute COVID-19 Syndrome prevention & control, SARS-CoV-2 drug effects
- Abstract
This exploratory analysis of the double-blind, phase 3, SCORPIO-SR trial assessed the effect of ensitrelvir in preventing post coronavirus disease 2019 (COVID-19) condition (PCC). Patients with mild-to-moderate COVID-19 were randomized (1:1:1) within 120 h of symptom onset; received 5-day oral ensitrelvir 125 mg (375 mg on day 1), 250 mg (750 mg on day 1), or a matching placebo once daily; and were assessed for the severity of typical PCC symptoms using a self-administered questionnaire. In total, 341, 317, and 333 patients were assessed in the ensitrelvir 125-mg, ensitrelvir 250-mg, and placebo groups, respectively (mean age, 35.6-36.5 years; men, 53.3%-58.3%). On days 85, 169, and 337, ensitrelvir 125-mg treatment showed 32.7% (95% confidence interval [CI]: -30.6, 66.1), 21.5% (95% CI: -37.3, 55.6), and 24.6% (95% CI: -43.7, 60.9) reductions versus placebo, respectively, in the risk of any of the 14 acute-phase COVID-19 symptoms (at least one mild, moderate, or severe symptom with general health not returning to the usual level). Ensitrelvir 250-mg treatment showed 10.9% (95% CI: -67.0, 52.8), 9.5% (95% CI: -56.6, 48.0), and 30.6% (95% CI: -36.2, 65.5) risk reductions versus placebo on days 85, 169, and 337, respectively. Risk reductions were observed in any of the 4 neurological symptoms and were more pronounced among patients with high acute-phase symptom scores at baseline and among those with a baseline body mass index ≥25 kg/m
2 . Ensitrelvir treatment in the acute phase of COVID-19 may reduce the risk of various symptoms associated with PCC. TRIAL REGISTRATION NUMBER: jRCT2031210350., Competing Interests: Declaration of competing interest Hiroshi Yotsuyanagi has received honoraria for lectures from Shionogi, MSD, Pfizer, and ViiV Healthcare, received travel and meeting support from Shionogi, and serves as an advisory board member of Shionogi and President of the Japanese Society of Infectious Diseases. Yohei Doi has received grants from Entasis and Shionogi; consulting fees from GSK, Moderna, Gilead Sciences, Shionogi, Fujifilm, Meiji Seika Pharma, Pfizer, and AbbVie; and lecture fees from Gilead and Shionogi. Masaya Yamato has received lecture fees from Shionogi. Akimasa Fukushi, Takumi Imamura, Hiroki Sakaguchi, Takuhiro Sonoyama, Takao Sanaki, Genki Ichihashi, Yuko Tsuge, and Takeki Uehara are full-time employees of Shionogi & Co., Ltd. and may hold stocks in the company. Hiroshi Mukae has received support for the present manuscript from Shionogi; consulting fees from Shionogi and MSD; and lecture fees from Shionogi, MSD, Gilead Sciences, AstraZeneca, Pfizer, and GSK. Norio Ohmagari has no conflict of interest., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
18. Pre-clinical and clinical evaluation of a surface plasmon field-enhanced fluorescence spectroscopy (SPFS) antigen test for detecting SARS-CoV-2.
- Author
-
Ashizawa N, Takazono T, Ota K, Ito Y, Hirayama T, Takeda K, Ide S, Iwanaga N, Fujita A, Tashiro M, Hosogaya N, Akamatsu N, Kosai K, Tanaka T, Kobayashi H, Yamauchi R, Segawa C, Koizumi H, Taka N, Hishigaki H, Yamamoto K, Izumikawa K, Yanagihara K, and Mukae H
- Abstract
Introduction: The diagnostic tools of nucleic acid amplification tests and antigen tests have been extensively employed for the detection of Coronavirus disease 2019 (COVID-19). Although the reverse-transcriptase polymerase chain reaction (RT)-PCR test has high sensitivity and specificity, it is a time-consuming and labor-intensive process. On the other hand, antigen tests are simple and prompt, however, their low sensitivity and potential for false positives have been identified as limitations. In light of these factors, the development of novel tests that combine speed and clinical dependability is a promising prospect., Methods: Surface plasmon field-enhanced fluorescence spectroscopy (SPFS) excites chromophores by means of an enhanced electromagnetic field induced on a gold film surface. It enables the highly sensitive measurement of biomarkers in a short and simple 20-min window. In this study, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) SPFS-based antigen test targeting the SARS-CoV-2 nucleocapsid protein was performed and evaluated in 25 patients with COVID-19 and 10 non-infected controls., Results: A positive correlation was observed between antigen levels determined by SPFS and RNA levels determined via RT-PCR. The sensitivity values were 100 %, 92 %, and 62.5 %; and the specificity values were 100 %, 90 %, and 100 %; for nasopharyngeal swabs, nasal swabs, and saliva specimens when the cutoff values were set to 65.1, 0.2, and 1.5 pg/mL, respectively. No clinically problematic cross-reactivity with analogous coronaviruses was observed., Conclusions: The SARS-CoV-2 SPFS antigen test showed excellent clinical diagnostic accuracy for nasopharyngeal and nasal swabs, with a rapid turnaround., (Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. Exposure and outcomes of aortic valve change in patients initiating dialysis.
- Author
-
Kitamura M, Yamashita H, Sawase A, Takeno M, Maemura K, Mukae H, and Nishino T
- Abstract
Background: Aortic stenosis (AS) and aortic valve calcification (AVC) are occasionally observed in patients receiving maintenance dialysis. However, their prevalence and factors associated with them in patients undergoing dialysis remain unknown. We aimed to elucidate the aortic valve status at the time of dialysis initiation and patient prognosis based on aortic valve status., Methods: We analyzed 289 patients initiating dialysis (hemodialysis: peritoneal dialysis = 275:14) between 2016 and 2023. "AS and/or AVC" was detected using echocardiography. AS was defined as a maximum transaortic velocity > 2.0 m/s. Statistical analyses including multivariable logistic regression and Cox regression were used to assess the association between patient characteristics and survival outcomes., Results: Aortic valve changes were observed in 121 (42%) patients, among which 33 (11%) met the AS criteria. The mean age of patients in the AS, AVC without AS, and control groups was 79.1 ± 8.9, 75.9 ± 9.2, and 68.3 ± 12.9, respectively (P < 0.001). Multivariable logistic regression models showed that only age was associated with aortic valve changes (P < 0.001). Age and other important factor-adjusted multivariable Cox regression models showed that AS was an independent risk factor for death after dialysis initiation (hazard ratio (HR): 1.95, 95% confidence interval (CI): 1.06 - 3.59, P = 0.04). However, aortic valve changes ("AS and/or AVC") were not a risk factor for death (HR: 1.51, 95% CI 0.95 - 2.39, P = 0.08)., Conclusions: With the growing older population undergoing dialysis, aortic valve changes should be closely monitored. Particularly, AS is crucial because of its impact on patient prognosis., (© 2024. The Author(s), under exclusive licence to Japanese Society of Nephrology.)
- Published
- 2024
- Full Text
- View/download PDF
20. Analysis of the Effector Functions of Vδ2 γδ T Cells and NK Cells against Cholangiocarcinoma Cells.
- Author
-
Kulma I, Na-Bangchang K, Carvallo Herrera A, Ndubuisi IT, Iwasaki M, Tomono H, Morita CT, Okamura H, Mukae H, and Tanaka Y
- Subjects
- Humans, Cell Line, Tumor, Bile Duct Neoplasms immunology, Bile Duct Neoplasms pathology, Cytotoxicity, Immunologic drug effects, T-Lymphocytes immunology, Intraepithelial Lymphocytes immunology, Cholangiocarcinoma immunology, Cholangiocarcinoma pathology, Killer Cells, Natural immunology, Receptors, Antigen, T-Cell, gamma-delta metabolism, Receptors, Antigen, T-Cell, gamma-delta immunology, Interferon-gamma metabolism
- Abstract
Cholangiocarcinoma (CCA) is a rare disease characterized by malignant cells derived from the epithelial cells of the biliary duct system. Despite extensive treatments, the prognosis for CCA remains poor, emphasizing the critical need for the development of novel treatments. Considerable attention has been directed towards innate immune effector cells, which can recognize tumor cells independently of the major histocompatibility complex, laying the foundation for the development of off-the-shelf drugs. In this study, we cultured innate immune cells obtained from the peripheral blood of healthy adults and conducted a comparative analysis of the effector functions against CCA cell lines by Vδ2 γδ T cells and NK cells. This analysis was performed using standard short- and long-term cytotoxicity assays, as well as ELISA for IFN-γ. Vδ2 γδ T cells demonstrated cytotoxicity and IFN-γ production in response to CCA cells in a TCR-dependent manner, particularly in the presence of tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-bisphosphonate, a bisphosphonate prodrug. In contrast, direct killing and antibody-dependent cellular cytotoxicity were relatively slow and weak. Conversely, NK cells displayed potent, direct cytotoxicity against CCA cells. In summary, both Vδ2 γδ T cells and NK cells show promise as innate immune effector cells for adoptive transfer therapy in the context of CCA.
- Published
- 2024
- Full Text
- View/download PDF
21. Successful EGFR Mutation Detection in Cytological Specimens of Lung Cancer with Challenging Biopsies by Integrating Virtual Bronchoscopy Navigation and Endobronchial Ultrasound Guidance with Highly Sensitive Next-Generation Sequencing: A Case Report.
- Author
-
Umeyama Y, Soda H, Senju H, Ogata R, Iwanaga M, Hayashi H, Taniguchi H, Takemoto S, Takazono T, Sakamoto N, Fukuda Y, and Mukae H
- Abstract
Introduction: This case report presents the successful detection of an EGFR exon 19 deletion using virtual bronchoscopic navigation (VBN) and endobronchial ultrasound with guide sheath (EBUS-GS) brushing, integrated with highly sensitive next-generation sequencing (NGS), even in challenging biopsy scenarios. The growing prevalence of driver gene alterations in non-small cell lung cancer necessitates effective bronchoscopic technology and reliable multiplex gene NGS panels. However, data regarding the optimal bronchoscopic techniques when using highly sensitive NGS panels are limited. Herein, we report a case utilizing VBN-guided EBUS-GS brushing as an exploratory approach to address this challenge., Case Presentation: A 71-year-old man was evaluated for a band-like lesion near the left pleura during spinal cord infarction. Transbronchial specimens were obtained from lesions invisible on conventional chest radiography and X-ray fluoroscopy using VBN and EBUS-GS brushing. Cytological brushing specimens revealed lung adenocarcinoma, and highly sensitive NGS identified an EGFR exon 19 deletion. He was diagnosed with stage IB disease and underwent radical radiotherapy owing to his fragile condition. If recurrence occurs, the patient will be treated with an EGFR inhibitor., Conclusion: VBN-guided EBUS-GS brushing, a minimally invasive approach, combined with highly sensitive NGS has the potential to provide accurate molecular diagnoses to more patients with lung cancer, thereby offering opportunities for personalized treatment. Our findings warrant further investigation to determine optimal bronchoscopic technologies for obtaining tumor specimens., Competing Interests: The authors have no conflicts of interest to declare., (© 2024 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
22. Pulmonary Nocardiosis Caused by Nocardia sputorum Identified via 16S rRNA Gene Sequencing: A Case Report.
- Author
-
Irifune S, Ide S, Koga S, Mine K, Sugasaki N, Kosai K, Fukuda M, Yanagihara K, and Mukae H
- Abstract
Nocardia sputorum , a novel Nocardia species discovered in Japan in 2023, has not been reported to infect humans. Here, we report a case of pulmonary nocardiosis in a 70-year-old immunocompetent woman infected with N. sputorum . The patient presented to the hospital with a chief complaint of weight loss. She worked at a fruit sorting facility where she was exposed to dust. Chest computed tomography revealed a single cavity and diffuse nodular opacities in both lungs. Nocardia species was isolated from tracheal sputum and bronchial lavage fluid and identified as N. sputorum via 16S rRNA gene sequencing. The patient was treated with oral sulfamethoxazole and trimethoprim but developed oral mucositis on the 12th day of treatment. Consequently, minocycline was prescribed, and the patient's condition improved after a six-month course of treatment. To our knowledge, this is the first reported case of pulmonary nocardiosis caused by N. sputorum in humans. Accurate species identification and antimicrobial susceptibility tests will be necessary to prescribe appropriate treatment for Nocardia infections., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Irifune et al.)
- Published
- 2024
- Full Text
- View/download PDF
23. Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19.
- Author
-
Takazono T, Fujita S, Komeda T, Miyazawa S, Yoshida Y, Kitanishi Y, Kinoshita M, Kojima S, Shen H, Uehara T, Hosogaya N, Iwanaga N, and Mukae H
- Abstract
Introduction: This study aimed to evaluate the effectiveness of ensitrelvir, an oral antiviral, in reducing hospitalization risk in outpatients at high-risk for severe COVID-19 during the Omicron era., Methods: This was a retrospective study using a large Japanese health insurance claims database. It included high-risk outpatients for severe symptoms who received their first COVID-19 diagnosis between November 2022 and July 2023. The study included outpatients aged ≥ 18 years. The primary endpoint was all-cause hospitalization during the 4-week period from the date of outpatient diagnosis and medication, comparing the ensitrelvir group (n = 5177) and the no antiviral treatment group (n = 162,133). The risk ratio and risk difference were evaluated after adjusting patient background distribution by the inverse probability of treatment weight (IPTW) method. Secondary endpoints were incidence of respiratory and heart rate monitoring, oxygen therapy, ventilator use, intensive care admission, and all-cause death., Results: The risk ratio for all-cause hospitalization between the ensitrelvir group (n = 167,385) and the no antiviral treatment group (n = 167,310) after IPTW adjustment was 0.629 [95% confidence interval (CI) 0.420, 0.943]. The risk difference was - 0.291 [95% CI - 0.494, - 0.088]. The incidence of both respiratory and heart rate monitoring and oxygen therapy was lower in the ensitrelvir group. Ventilator use, intensive care admission, and all-cause death were difficult to assess because of the limited events., Conclusions: The incidence of all-cause hospitalization was significantly lower in the ensitrelvir group than in the no antiviral treatment group, suggesting ensitrelvir is an effective treatment in patients at risk of severe COVID-19., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
24. Development of a score model to predict long-term prognosis after community-onset pneumonia in older patients.
- Author
-
Takazono T, Namie H, Nagayoshi Y, Imamura Y, Ito Y, Sumiyoshi M, Ashizawa N, Yoshida M, Takeda K, Iwanaga N, Ide S, Harada Y, Hosogaya N, Takemoto S, Fukuda Y, Yamamoto K, Miyazaki T, Sakamoto N, Obase Y, Sawai T, Higashiyama Y, Hashiguchi K, Funakoshi S, Suyama N, Tanaka H, Yanagihara K, Izumikawa K, and Mukae H
- Subjects
- Humans, Female, Male, Prognosis, Aged, Aged, 80 and over, Prospective Studies, Risk Factors, Anti-Bacterial Agents therapeutic use, Predictive Value of Tests, Dementia diagnosis, Dementia epidemiology, Community-Acquired Infections microbiology, Community-Acquired Infections diagnosis, Community-Acquired Infections drug therapy, Pneumonia diagnosis, Pneumonia microbiology, Pneumonia drug therapy, Pneumonia mortality
- Abstract
Background and Objective: The identification of factors associated with long-term prognosis after community-onset pneumonia in elderly patients should be considered when initiating advance care planning (ACP). We aimed to identify these factors and develop a prediction score model., Methods: Patients aged 65 years and older, who were hospitalized for pneumonia at nine collaborating institutions, were included. The prognosis of patients 180 days after the completion of antimicrobial treatment for pneumonia was prospectively collected., Results: The total number of analysable cases was 399, excluding 7 outliers and 42 cases with missing data or unknown prognosis. These cases were randomly divided in an 8:2 ratio for score development and testing. The median age was 82 years, and there were 68 (17%) deaths. A multivariate analysis showed that significant factors were performance status (PS) ≥2 (Odds ratio [OR], 11.78), hypoalbuminemia ≤2.5 g/dL (OR, 5.28) and dementia (OR, 3.15), while age and detection of antimicrobial-resistant bacteria were not associated with prognosis. A scoring model was then developed with PS ≥2, Alb ≤2.5, and dementia providing scores of 2, 1 and 1 each, respectively, for a total of 4. The area under the curve was 0.8504, and the sensitivity and specificity were 94.6% and 61.7% at the cutoff of 2, respectively. In the test cases, the sensitivity and specificity were 91.7% and 63.1%, respectively, at a cutoff value of 2., Conclusion: Patients meeting this score should be considered near the end of life, and the initiation of ACP practices should be considered., (© 2024 Asian Pacific Society of Respirology.)
- Published
- 2024
- Full Text
- View/download PDF
25. Molecular and phenotypic characterization of Streptococcus pneumoniae isolates in a Japanese tertiary care hospital.
- Author
-
Nakao T, Kosai K, Akamatsu N, Ota K, Mitsumoto-Kaseida F, Hasegawa H, Izumikawa K, Mukae H, and Yanagihara K
- Subjects
- Humans, Japan, Young Adult, Adolescent, Phenotype, Aged, Middle Aged, Adult, Bacterial Proteins genetics, Female, Male, Methyltransferases genetics, Aged, 80 and over, East Asian People, Membrane Proteins, Streptococcus pneumoniae drug effects, Streptococcus pneumoniae genetics, Streptococcus pneumoniae isolation & purification, Streptococcus pneumoniae classification, Tertiary Care Centers, Microbial Sensitivity Tests, Pneumococcal Infections microbiology, Anti-Bacterial Agents pharmacology, Macrolides pharmacology, Serogroup, Drug Resistance, Bacterial genetics
- Abstract
This study aimed to investigate the bacterial characteristics of pneumococcal isolates obtained from a tertiary care hospital in Japan. We analyzed the antimicrobial susceptibility, possession of macrolide resistance genes, pneumococcal serogroup/serotype, and sequence type (ST) of pneumococcal isolates from patients aged 15 years or older between 2011 and 2020 at Nagasaki University Hospital. Of the 73 isolates analyzed, 86.3% showed resistance to macrolides, and 28.8%, 46.6%, and 11.0% harbored mefA , ermB , and both, respectively. Of the isolates possessing ermB , 97.6% showed high levels of macrolide resistance [minimal inhibitory concentration (MIC) range, > 16 µg/mL]. Solithromycin (MIC range, 0.03-0.25 µg/mL), regardless of the presence of macrolide resistance genes, and lascufloxacin (MIC range, 0.06-0.5 µg/mL) showed potent in vitro activity against pneumococci. Serotype 19A was the most prevalent (six isolates), followed by serotypes 10A, 15A, and 15B/C (five isolates each). Four serotypes (11A, 19A, 22F, and 23B) and five STs (36, 99, 433, 558, and 3111) were significantly correlated with the presence of macrolide resistance genes. All four isolates with serotype 11A/ST99 and three isolates with serotype 19A/ST3111 harbored both mefA and ermB . No macrolide resistance genes were detected in either of the two isolates with serotype 22F/ST433, while all ten isolates with serogroup 15 (serotypes 15A and 15B/C, five isolates each) possessed ermB alone. Our study revealed the bacterial characteristics of the pneumococcal isolates obtained from our hospital. In vitro activity of solithromycin and lascufloxacin against these isolates was confirmed., Competing Interests: Solithromycin and lascufloxacin were provided by FUJIFILM Toyama Chemical Co., Ltd. and Kyorin Pharmaceutical Co., Ltd., respectively., (Copyright © 2024 Nakao, Kosai, Akamatsu, Ota, Mitsumoto-Kaseida, Hasegawa, Izumikawa, Mukae and Yanagihara.)
- Published
- 2024
- Full Text
- View/download PDF
26. Cases of Fabry Disease in Which Pathogenic Variants Are Not Detected in Parent-Child Pairs.
- Author
-
Akeho N, Muta K, Torigoe K, Kitamura M, Sawada T, Nakamura K, Mukae H, and Nishino T
- Abstract
A 15-year-old male has been experiencing fever, limb pain during exercise, and reduced sweating since childhood. During an investigation into his fever, a family history of Fabry disease was discovered, prompting a referral to our department. He was diagnosed with Fabry disease based on decreased alpha-galactosidase A (α-Gal A) activity. Concurrently, his mother was found to have experienced limb pain during fevers since childhood, and she was also diagnosed with Fabry disease based on decreased α-Gal A activity. In the genetic analysis of both individuals, the IVS1+17A>G GLA variant was identified. This variant is considered benign and not classified as a pathogenic variant. Enzyme replacement therapy has been effective in improving clinical symptoms. His sister, who has not been diagnosed with Fabry disease due to normal clinical symptoms and α-GAL A activity, also had the same variant. Among the various GLA variants, many are classified as benign rather than pathogenic. In the present cases, the possibility of other factors that cannot be identified by genetic analysis is suggested, making this case significant and worth reporting., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Akeho et al.)
- Published
- 2024
- Full Text
- View/download PDF
27. Novel method of attaching a suction tube externally to a tracheal tube as an insertion route for a Fogarty catheter in cryobiopsy: Retrospective comparative study.
- Author
-
Ishimoto H, Sakamoto N, Okuno D, Yura H, Ozasa M, Miyashita R, Tokito T, Kido T, Takemoto S, Takazono T, Obase Y, Ishimatsu Y, Nishino T, and Mukae H
- Subjects
- Humans, Retrospective Studies, Suction instrumentation, Suction methods, Male, Female, Aged, Biopsy methods, Biopsy instrumentation, Middle Aged, Catheters, Cryosurgery methods, Cryosurgery instrumentation, Intubation, Intratracheal instrumentation, Intubation, Intratracheal methods, Bronchoscopy methods
- Abstract
Background: Cryobiopsy use is anticipated to become more common in diagnosing lung diseases. In Japan, inserting a Fogarty catheter through a suction channel above the endotracheal tube's cuff for hemostasis is common practice. However, the rigid nature of the endotracheal tube poses challenges to tracheal intubation using a bronchoscope. The endotracheal tube cuff must be removed to prevent interference during Fogarty catheter insertion. To simplify the procedure and enhance safety, we devised and implemented a method of inserting a hemostatic Fogarty catheter with a suction tube externally attached to a softer endotracheal tube. This study aimed to evaluate the sustainability of this Fogarty catheter insertion method using suction tubes., Methods: The hemostatic Fogarty catheter insertion method was retrospectively validated. We compared outcomes between 60 patients who underwent the conventional method with a suction channel above the cuff and 50 patients who underwent the novel approach with an externally attached suction tube., Results: The physicians performing bronchoscopy and inserting the Fogarty catheter in the group in which the suction tube was externally attached for Fogarty catheter insertion had little experience. However, the overall bronchoscopy time was shorter; the two groups showed no significant differences in complications., Conclusion: Regarding cryobiopsy procedures, using an externally attached suction tube for Fogarty catheter insertion was practical and comparable to the conventional method of using a suction channel above the cuff. This method made the procedure more simple and safe., Competing Interests: Declaration of competing interest The authors have no conflicts of interest., (Copyright © 2024 The Author. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Pulmonary function and chest CT abnormalities 3 months after discharge from COVID-19, 2020-2021: A nation-wide multicenter prospective cohort study from the Japanese respiratory society.
- Author
-
Kamata H, Takamatsu K, Fukunaga K, Chubachi S, Nakagawara K, Namkoong H, Terai H, Tanaka K, Sato S, Hagiwara E, Takei R, Kondoh Y, Takazono T, Hashimoto M, Tasaka S, Ohrui T, Tanino Y, Mineshita M, Komase Y, Miyazaki K, Nishikawa M, Ando A, Kita H, Ichihara E, Ohshimo S, Murata Y, Ishida M, Kobayashi S, Uchida T, Tateno H, Ikari J, Terashima T, Kozu Y, Tateishi T, Shinkai M, Sagara H, To Y, Ito Y, Yamamoto M, Yamamoto Y, Kita T, Ito Y, Tomii K, Fujita Y, Funaki Y, Yatera K, Yamasue M, Komiya K, Kozawa S, Manabe H, Hozumi H, Horiguchi T, Kitajima T, Nakano Y, Nagaoka T, Hojo M, Ebihara A, Kobayashi M, Takayama K, Jinta T, Sawai T, Fukuda Y, Kaneko T, Chin K, Ogura T, Mukae H, Ishii M, and Yokoyama A
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Cohort Studies, Dyspnea etiology, East Asian People, Japan epidemiology, Patient Discharge, Prospective Studies, Respiratory Function Tests, Severity of Illness Index, Societies, Medical, Time Factors, Tomography, X-Ray Computed, COVID-19 complications, COVID-19 diagnostic imaging, COVID-19 epidemiology, Lung diagnostic imaging, Lung physiopathology
- Abstract
Background: No comprehensive analysis of the pulmonary sequelae of coronavirus disease 2019 (COVID-19) in Japan based on respiratory function tests and chest computed tomography (CT) has been reported. We evaluated post-COVID-19 conditions, especially focusing on pulmonary sequelae assessed by pulmonary function tests and chest CT., Methods: For this prospective cohort study, we enrolled 1069 patients who presented pneumonia at the time of admission in 55 hospitals from February 2020 to September 2021. Disease severity was classified as moderateⅠ, moderate II, and severe, defined primarily according to the degree of respiratory failure. The data on post-COVID-19 conditions over 12 months, pulmonary function, and chest CT findings at 3 months were evaluated in this study. Additionally, the impact of COVID-19 severity on pulmonary sequelae, such as impaired diffusion capacity, restrictive pattern, and CT abnormalities, was also evaluated., Results: The most frequently reported post-COVID-19 conditions at 3 months after COVID-19 were muscle weakness, dyspnea, and fatigue (48.4%, 29.0%, and 24.7%, respectively). The frequency of symptoms gradually decreased over subsequent months. In pulmonary function tests at 3 months, the incidence of impaired diffusion capacity and restrictive pattern increased depending on disease severity. There also were differences in the presence of chest CT abnormalities at the 3 months, which was markedly correlated with the severity., Conclusion: We reported a comprehensive analysis of post-COVID-19 condition, pulmonary function, and chest CT abnormalities in Japanese patients with COVID-19. The findings of this study will serve as valuable reference data for future post-COVID-19 condition research in Japan., Competing Interests: Declaration of Competing interest The authors have no conflicts of interest., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
29. Epidemiologic evaluation of pulmonary paragonimiasis in Japan using a Japanese nationwide administrative database.
- Author
-
Ikushima I, Yamasaki K, Tahara M, Nemoto K, Akata K, Ikegami H, Nishida C, Muramatsu K, Fujino Y, Matsuda S, Fushimi K, Mukae H, and Yatera K
- Subjects
- Humans, Japan epidemiology, Male, Female, Middle Aged, Adult, Aged, Length of Stay statistics & numerical data, Lung Diseases, Parasitic epidemiology, Lung Diseases, Parasitic parasitology, Lung Diseases, Parasitic drug therapy, Young Adult, Hospitalization statistics & numerical data, Praziquantel therapeutic use, Adolescent, Animals, Comorbidity, East Asian People, Paragonimiasis epidemiology, Databases, Factual
- Abstract
Background: Paragonimiasis is a parasitic disease primarily contracted through consumption of undercooked freshwater crustaceans or wild boar meat. Large-scale nationwide epidemiological data on paragonimiasis are lacking. In this study, we aimed to investigate the nationwide epidemiology of hospitalized patients with paragonimiasis in Japan using a comprehensive nationwide Japanese administrative database., Methods: We evaluated the Japanese Diagnosis Procedure Combination (DPC) data of patients diagnosed with pulmonary paragonimiasis between April 1, 2012 and March 30, 2020. The patients' address and information, including age, sex, treatment (medication: praziquantel; surgery: open thoracotomy or intracranial mass extirpation), Japan coma scale, comorbidities, and length of hospital stay, were extracted., Results: Of the 49.6 million hospitalized patients, data were extracted on 73 patients with paragonimiasis, of whom 36 were male and 37 were female. The mean age was 49.7 years and the mean length of stay was 12.5 days. The most frequent comorbidity was pleural effusion (31.5 %), followed by pneumothorax (13.7 %). The sites of ectopic paragonimiasis in organs other than the lung included the liver (5.5 %), skin (4.1 %), and brain (2.7 %). Geographically, most patients were from the Kyushu region (54.8 %), followed by the Kanto region (22.0 %). Fukuoka Prefecture had the highest number of patients (22.0 %) by prefecture. During the study period, an average of 9.1 patients/year were hospitalized with lung paragonimiasis in Japan., Conclusion: Paragonimiasis has not completely disappeared in Japan; thus, physicians should be aware of paragonimiasis in the Kyushu region, especially in the Fukuoka Prefecture., Competing Interests: Declaration of competing interest None., (Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. Efficacy and safety of lascufloxacin for nursing- and healthcare-associated pneumonia: A single-arm, open-label clinical trial.
- Author
-
Takazono T, Hosogaya N, Fukushima K, Morio R, Irifune S, Miyamura T, Harada Y, Nagayoshi Y, Kondo A, Mihara T, Fukuda Y, Sasaki E, Sawai T, Imamura Y, Morikawa T, Futsuki Y, Inoue Y, Fukushima K, Suyama N, Tanaka H, Hanaka T, Shimabukuro I, Hata R, Ota K, Morimoto S, Nakada N, Ito Y, Yoshida M, Takeda K, Ide S, Iwanaga N, Nemoto K, Funada M, Izumikawa K, Yatera K, Yanagihara K, and Mukae H
- Subjects
- Humans, Male, Female, Aged, 80 and over, Aged, Japan, Treatment Outcome, Administration, Oral, Middle Aged, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents administration & dosage, Fluoroquinolones therapeutic use, Fluoroquinolones adverse effects, Fluoroquinolones administration & dosage, Healthcare-Associated Pneumonia drug therapy, Healthcare-Associated Pneumonia microbiology
- Abstract
Background: Nursing- and healthcare-associated pneumonia (NHCAP) constitutes most of the pneumonia in elderly patients including aspiration pneumonia in Japan. Lascufloxacin (LSFX) possesses broad antibacterial activity against respiratory pathogens, such as Streptococcus spp. And anaerobes inside the oral cavity. However, the efficacy and safety of LSFX in NHCAP treatment remains unknown. We aimed to evaluate the efficacy and safety of LSFX tablets in the treatment of patients with NHCAP., Methods: In this single-arm, open-label, uncontrolled study, LSFX was administered to patients with NHCAP at 24 facilities. The study participants were orally administered 75 mg LSFX once daily for 7 days. The primary endpoint was the clinical efficacy at the time of test of cure (TOC). The secondary endpoints included clinical efficacy at the time of end of treatment (EOT), early clinical efficacy, microbiological efficacy, and safety analysis., Result: During the study period, 75 patients provided written informed consent to participate and were included. Finally, 56 and 71 patients were eligible for clinical efficacy and safety analyses, respectively. The median age of the patients was significantly high at 86 years. All patients were classified as having moderate disease severity using the A-DROP scoring system. LSFX tablets demonstrated high efficacy rates of 78.6 % at TOC and 89.3 % at EOT. The risk factors for resistant bacteria or aspiration pneumonia did not affect clinical efficacy. No severe adverse events associated with the study drugs were observed., Conclusion: Oral LSFX is an acceptable treatment option for moderate NHCAP in elderly patients who can take oral medications., Competing Interests: Declaration of competing interest Hiroshi Mukae received lecture honoraria and research grants from KYORIN Pharmaceutical Co., Ltd. Outside of the submitted work., (Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Unplanned hemodialysis initiation: A retrospective analysis of patient characteristics and prognosis in an emergency hospital.
- Author
-
Kitamura M, Yamashita H, Sugiyama S, Kuroki R, Fukuda H, Sawase A, Tsuchiyama A, Takehara K, Watanabe J, Takazono T, Imamura R, Mukae H, and Nishino T
- Abstract
Introduction: Functional decline occurs during dialysis initiation, particularly in unplanned cases. To prevent unplanned hemodialysis, we aimed to identify associated factors from the first referral to the nephrology department to hemodialysis initiation and assess patient prognosis post-unplanned hemodialysis initiation., Methods: This retrospective study involved 257 Japanese patients initiating hemodialysis and compared patient characteristics based on whether hemodialysis was planned or unplanned at a single center. Patient outcomes were evaluated in collaboration with maintenance hemodialysis centers., Results: Unplanned hemodialysis initiation correlated with heart failure history (p < 0.05) and infections like pneumonia (p < 0.001). Patients with unplanned hemodialysis initiation had a worse prognosis than those with planned initiation (p < 0.001), and multivariable Cox regression showed it as an independent risk factor for death (p < 0.05)., Conclusions: Hygiene and careful attention to heart failure may reduce unplanned hemodialysis and improve patient well-being and healthcare efficiency. This retrospective analysis highlights crucial considerations for optimizing the initiation of hemodialysis., (© 2024 International Society for Apheresis and Japanese Society for Apheresis.)
- Published
- 2024
- Full Text
- View/download PDF
32. Tubulointerstitial nephritis with storiform fibrosis in a patient with angioimmunoblastic T-cell lymphoma.
- Author
-
Fukuda H, Kitamura M, Sawase A, Uramatsu T, Yamashita H, Tsushima H, Irie J, Katafuchi E, Kato S, Takeuchi M, Ohshima K, Nakayama T, Mukae H, and Nishino T
- Abstract
We present a case of an angioimmunoblastic T-cell lymphoma (AITL) and tubulointerstitial nephritis with storiform fibrosis in a 76-year-old man. The patient exhibited lymphadenopathy, polyclonal hypergammaglobulinemia, and renal dysfunction and was diagnosed with AITL on the basis of lymph node biopsy findings. The serum IgG4 level was highly elevated. Renal biopsy revealed IgG4-positive plasma cells and storiform fibrosis without infiltration of AITL, and the findings indicated IgG4-related kidney disease (IgG4-RKD). Following THPCOP therapy for AITL, the renal function improved. While diagnosing IgG4-RKD in a patient with AITL poses challenges, follicular helper T cell involvement appeared crucial in AITL and renal tubulointerstitial lesions in this case., (© 2024. The Author(s), under exclusive licence to Japanese Society of Nephrology.)
- Published
- 2024
- Full Text
- View/download PDF
33. Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough: Dose-Response Model-Based Network Meta-Analysis.
- Author
-
Yamamoto S, Horita N, Hara J, Sasamoto M, Kanemitsu Y, Hara Y, Obase Y, Kaneko T, Niimi A, and Mukae H
- Abstract
Background: Refractory or unexplained chronic cough disrupts quality of life and burdens health care systems around the world. The P2X3 receptor antagonist gefapixant is approved in many countries for its antitussive effects, but taste disturbances are a common adverse effect. Four newer, more selective P2X3 receptor antagonists have been developed to address this problem., Research Question: How does the benefit-risk profile vary across the five available P2X3 receptor antagonists?, Study Design and Methods: A systematic review and network meta-analysis was conducted to evaluate the efficacy of P2X3 receptor antagonists, including gefapixant, sivopixant, eliapixant, camlipixant, and filapixant. Primary outcomes were a reduction rate in 24-h cough frequency and incidence of taste disturbance. Dose-response curves and median effective dose (ED
50 ) were calculated. Effect size at ED50 was ranked according to the surface under the cumulative ranking curve. The confidence was evaluated by Confidence In Network Meta-Analysis., Results: Sixteen randomized controlled trials involving 4,904 participants were analyzed. The gefapixant regimen demonstrated an ED50 of 90.7 mg/d for cough frequency reduction. Gefapixant showed the highest antitussive effectiveness at ED50 (reduction rate in 24-h cough frequency: median, 28.1%; 95% credible interval [CrI], 21.0%-35.6%; ranked 1 of 5; moderate certainty) but the highest prevalence of taste disturbance (absolute risk difference per 100 patients: median, 38; 95% CrI, 27-51; ranked 5 of 5; high certainty) and the highest prevalence of discontinuation. Camlipixant had a well-balanced profile (reduction rate in 24-h cough frequency: median, 14.7%; 95% CrI, 5.4%-26.0%; ranked 3 of 5; low certainty; and taste disturbance; absolute risk difference per 100 patients; median, 2; 95% CrI, 1-6; ranked 2 of 5; low certainty). Placebo had a mean of 33.1% reduction in 24-h cough frequency., Interpretation: When used at safe doses, gefapixant had a favorable risk-benefit profile compared with the other four agents. Camlipixant showed initial promise, which may be further investigated by phase III trials currently underway., Clinical Trial Registration: UMIN000050622; URL., Competing Interests: Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: S. Y. has received overseas scholarships from the Japan Society for Promotion of Science. Y. K., Y. O., T. K., and H. M. received honoraria from Kyorin Pharmaceutical Co Ltd. A. N. received honoraria from Kyorin Pharmaceutical Co Ltd and MSD K.K. None declared (N. H., J. H., M. S., and Y. H.)., (Copyright © 2024 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
34. Aspartame, as an artificial sweetener, does not affect renal function and antioxidative states in mice.
- Author
-
Torigoe K, Torigoe M, Oka S, Obata Y, Mukae H, and Nishino T
- Subjects
- Animals, Mice, Male, Antioxidants pharmacology, Antioxidants metabolism, Superoxide Dismutase metabolism, Blood Urea Nitrogen, Aspartame pharmacology, Kidney drug effects, Kidney metabolism, Sweetening Agents pharmacology, Sweetening Agents administration & dosage, Mice, Inbred ICR, Oxidative Stress drug effects
- Abstract
Background and Objective: Aspartame (L-aspartyl L-phenylalanine methyl ester) is an artificial sweetener widely used as a sugar substitute. There are concerns regarding the effects of high aspartame doses on the kidney owing to oxidative stress; however, whether the maximum allowed dose of aspartame in humans affects the kidneys remains unknown. Therefore, in this study, we investigated whether the maximum allowed dose of aspartame in humans affects the kidneys., Methods: In this study, animals were fed a folate-deficient diet to mimic human aspartame metabolism. Eight-week-old ICR mice were divided into control (CTL), 40 mg/kg/day of aspartame-administered (ASP), folate-deficient diet (FD), and 40 mg/kg/day of aspartame-administered with a folate-deficient diet (FD + ASP) groups. Aspartame was administered orally for eight weeks. Thereafter, we evaluated aspartame's effect on kidneys via histological analysis., Results: There were no differences in serum creatinine and blood urea nitrogen levels between the CTL and ASP groups or between the FD and FD + ASP groups. There was no histological change in the kidneys in any group. The expression of superoxide dismutase and 4-hydroxy-2-nonenal in the kidney did not differ between the CTL and ASP groups or the FD and FD + ASP groups., Conclusion: Our findings indicate that the allowed doses of aspartame in humans may not affect kidney function or oxidative states., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
35. Utility of pneumonia severity assessment tools for mortality prediction in healthcare-associated pneumonia: a systematic review and meta-analysis.
- Author
-
Noguchi S, Katsurada M, Yatera K, Nakagawa N, Xu D, Fukuda Y, Shindo Y, Senda K, Tsukada H, Miki M, and Mukae H
- Subjects
- Humans, Prognosis, Area Under Curve, Healthcare-Associated Pneumonia mortality, Healthcare-Associated Pneumonia diagnosis, Severity of Illness Index
- Abstract
Accurate prognostic tools for mortality in patients with healthcare-associated pneumonia (HCAP) are needed to provide appropriate medical care, but the efficacy for mortality prediction of tools like PSI, A-DROP, I-ROAD, and CURB-65, widely used for predicting mortality in community-acquired and hospital-acquired pneumonia cases, remains controversial. In this study, we conducted a systematic review and meta-analysis using PubMed, Cochrane Library (trials), and Ichushi web database (accessed on August 22, 2022). We identified articles evaluating either PSI, A-DROP, I-ROAD, or CURB-65 and the mortality outcome in patients with HCAP, and calculated the pooled sensitivities, specificities, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and the summary area under the curves (AUCs) for mortality prediction. Additionally, the differences in predicting prognosis among these four assessment tools were evaluated using overall AUCs pooled from AUC values reported in included studies. Eventually, 21 articles were included and these quality assessments were evaluated by QUADAS-2. Using a cut-off value of moderate in patients with HCAP, the range of pooled sensitivity, specificity, PLR, NLR, and DOR were found to be 0.91-0.97, 0.15-0.44, 1.14-1.66, 0.18-0.33, and 3.86-9.32, respectively. Upon using a cut-off value of severe in those patients, the range of pooled sensitivity, specificity, PLR, NLR, and DOR were 0.63-0.70, 0.54-0.66, 1.50-2.03, 0.47-0.58, and 2.66-4.32, respectively. Overall AUCs were 0.70 (0.68-0.72), 0.70 (0.63-0.76), 0.68 (0.64-0.73), and 0.67 (0.63-0.71), respectively, for PSI, A-DROP, I-ROAD, and CURB-65 (p = 0.66). In conclusion, these severity assessment tools do not have enough ability to predict mortality in HCAP patients. Furthermore, there are no significant differences in predictive performance among these four severity assessment tools., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
36. Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID-19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial.
- Author
-
Ohmagari N, Yotsuyanagi H, Doi Y, Yamato M, Imamura T, Sakaguchi H, Yamanaka H, Imaoka R, Fukushi A, Ichihashi G, Sanaki T, Tsuge Y, Uehara T, and Mukae H
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Antiviral Agents therapeutic use, Antiviral Agents adverse effects, Treatment Outcome, Asymptomatic Infections, Vietnam, Japan, Aged, Republic of Korea, Young Adult, Indazoles, Triazines, Triazoles, SARS-CoV-2 drug effects, COVID-19 Drug Treatment, COVID-19 virology
- Abstract
Background: This phase 2b/3, randomized, placebo-controlled trial explored the efficacy and evaluated the safety of ensitrelvir. This trial involved individuals with asymptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and patients with mild symptoms of coronavirus disease 2019 (COVID-19)., Methods: The trial was conducted at 57 medical institutions in Japan, South Korea, and Vietnam (study period: January 6-August 14, 2022). Eligible participants were randomized (1:1:1) to the ensitrelvir 125-mg, ensitrelvir 250-mg, or placebo group, received the allocated intervention orally, and were followed up until Day 28. Participants self-rated the severity of 14 typical COVID-19 symptoms and recorded the data in an electronic diary., Results: In total, 572 participants (194, 189, and 189 in the ensitrelvir 125-mg, ensitrelvir 250-mg, and placebo groups, respectively) were included in the intention-to-treat population. Ensitrelvir 125-mg group observed a 77% reduction in the risk of developing any of the 14 COVID-19 symptoms or fever and a 29% reduction in the risk of worsening of such symptoms or fever versus placebo (statistically nonsignificant). The viral RNA, viral titer, and time to infectious viral clearance observed a statistically significant decrease versus placebo. Most treatment-related adverse events (TEAEs) were mild to moderate in severity, and the most common TEAE observed across groups was a decrease in high-density lipoprotein., Conclusions: Our exploratory results suggest a potential reduction in the risk of development or worsening of COVID-19 symptoms with ensitrelvir. Ensitrelvir showed antiviral efficacy and was well tolerated., Trial Registration: Japan Registry of Clinical Trials identifier: jRCT2031210350., (© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
37. Hereditary Hemorrhagic Telangiectasia in a Patient Undergoing Hemodialysis with Anticoagulants and Antiplatelets.
- Author
-
Otsuka E, Kitamura M, Sawase K, Nakamura M, Inoue H, Yamaguchi K, Funakoshi S, Takazono T, Mukae H, and Nishino T
- Subjects
- Humans, Middle Aged, Female, Fatal Outcome, Telangiectasia, Hereditary Hemorrhagic complications, Renal Dialysis adverse effects, Anticoagulants adverse effects, Anticoagulants therapeutic use, Platelet Aggregation Inhibitors adverse effects, Platelet Aggregation Inhibitors therapeutic use
- Abstract
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder that causes abnormal blood vessel formation and bleeding. We herein report a 61-year-old woman with aggravated HHT symptoms after hemodialysis initiation. She was diagnosed with HHT based on her recurrent bleeding, abnormal blood vessel formation, and family history. Despite bleeding complications, the patient required anticoagulants and antiplatelet agents to treat cardiovascular complications. Eventually, the patient died of extensive cerebral hemorrhaging. Our experience suggests that special attention should be paid to bleeding complications in high-risk patients.
- Published
- 2024
- Full Text
- View/download PDF
38. Serum Cytokine Changes in a Patient with Chronic Pulmonary Aspergillosis Overlapping with Allergic Bronchopulmonary Aspergillosis.
- Author
-
Tsukamoto Y, Ito Y, Obase Y, Takazono T, Nakada N, Ashizawa N, Hirayama T, Takeda K, Ide S, Iwanaga N, Tashiro M, Hosogaya N, Fukahori S, Fukushima C, Yanagihara K, Izumikawa K, and Mukae H
- Subjects
- Humans, Chronic Disease, Antifungal Agents therapeutic use, Male, Middle Aged, Aspergillosis, Allergic Bronchopulmonary blood, Aspergillosis, Allergic Bronchopulmonary drug therapy, Aspergillosis, Allergic Bronchopulmonary diagnosis, Aspergillosis, Allergic Bronchopulmonary complications, Pulmonary Aspergillosis blood, Pulmonary Aspergillosis diagnosis, Pulmonary Aspergillosis drug therapy, Pulmonary Aspergillosis complications, Cytokines blood, Voriconazole therapeutic use
- Abstract
Allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA) are diseases caused by Aspergillus infection, and CPA can develop from ABPA in some cases. We herein report a patient with CPA overlapping with ABPA. Serum cytokine levels were evaluated at 4 time points: the ABPA diagnosis, CPA diagnosis, 6 months after the start of voriconazole (VRCZ), and 12 months after re-administration of VRCZ. Interleukin (IL)-13 levels decreased upon glucocorticoid treatment, whereas IL-25 and IL-33 levels decreased rapidly with the initiation of antifungals. Early antifungal therapy may be important to control disease progression and prevent CPA overlap.
- Published
- 2024
- Full Text
- View/download PDF
39. Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis.
- Author
-
Otsuka E, Kitamura M, Funakoshi S, Mukae H, and Nishino T
- Abstract
Background: Tirzepatide-a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist-is used to treat type 2 diabetes. However, the efficacy and safety of tirzepatide in patients undergoing hemodialysis remain unclear. Methods: We conducted a single-center retrospective study of patients with type 2 diabetes undergoing hemodialysis who were transitioned from dulaglutide to tirzepatide. We continuously monitored glucose levels in patients undergoing hemodialysis before and after switching from dulaglutide to tirzepatide. Results: Fourteen patients (mean age: 61.9 ± 9.9 years, male: female = 11:3) were included in this study. After switching to tirzepatide, time in range increased to 50.8% from 42.7% ( p = 0.02), time above range decreased to 37.8% from 48.4% ( p = 0.02), and mean glucose levels decreased to 137.4 mg/dL from 156.6 mg/dL ( p = 0.006). In contrast, there was no significant difference in time below range before and after tirzepatide administration (11.3% and 8.9%) ( p = 0.75). Three patients experienced dyspepsia (21.4%), and one patient experienced nausea (7.1%); however, no critical adverse events were reported. Conclusion: Transitioning from dulaglutide to tirzepatide improved glycemic control without increasing hypoglycemia in patients undergoing hemodialysis for type 2 diabetes., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Otsuka, Kitamura, Funakoshi, Mukae and Nishino.)
- Published
- 2024
- Full Text
- View/download PDF
40. Iron Deficiency in Newly Referred Patients With Chronic Renal Failure.
- Author
-
Kitamura M, Yamashita H, Kuroki R, Fukuda H, Sawase A, Mukae H, and Nishino T
- Abstract
Addressing iron deficiency is the key to managing anemia in patients with chronic kidney disease (CKD). Erythropoiesis-stimulating agents (ESAs) and hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs) are being prescribed to an increasing number of patients with CKD by primary physicians following the emergence of newer agents for the management of renal anemia. Among the 361 (average age: 76.8±12.1 years; 54.0% males) patients with stages 4 and 5 CKD newly referred to the nephrology department of our hospital between 2018 and 2023 who had evaluable transferrin saturation (TSAT) and ferritin levels, 169 patients (47%) had iron deficiency (ferritin <100 ng/mL or ferritin 100-300 ng/mL with TSAT <20%). The estimated glomerular filtration rate (eGFR), hemoglobin level, TSAT, and median ferritin level were 17.0±7.0 mL/min/1.73 m², 10.8±2.1 g/dL, 27.5±13.1%, and 130 ng/mL, respectively. ESAs, HIF-PHIs, and iron supplements were prescribed to 35 (9.7%), 17 (4.7%), and 35 (9.4%) patients, respectively. No significant differences were observed between the iron indices of the ESA group; however, the serum ferritin levels in the HIF-PHIs group were significantly lower than in those in the no-medication group (P=0.02). Multivariable logistic regression analysis revealed that age, female sex, eGFR, medications for renal anemia, and a history of ischemic heart disease were associated with iron deficiency (P<0.05). Although patients with renal failure tend to exhibit anemia, attention should be paid to iron deficiency anemia in addition to renal anemia, especially in patients with renal failure and a history of ischemic heart disease., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2024, Kitamura et al.)
- Published
- 2024
- Full Text
- View/download PDF
41. Clinical phenotype of anaerobic bacteremia unaccompanied by detectable abscess lesion: a 10-year retrospective, multicenter, observational-cohort study.
- Author
-
Nagaoka K, Iwanaga N, Murai Y, Kawasuji H, Miura M, Sato Y, Ito H, Terasaki Y, Takazono T, Kosai K, Sugano A, Morinaga Y, Yanagihara K, Mukae H, and Yamamoto Y
- Abstract
Purpose: Despite the importance of abscess lesions in clinical decisions regarding anaerobic bacteremia (AB), their impact on clinical characteristics remains unclear. Herein, we aimed to elucidate the clinical factors associated with AB that were unaccompanied by detectable abscess lesions during the initial phase of infection., Methods: This was a multicenter retrospective observational study involving patients with culture-proven AB at six tertiary hospitals in Japan between January 2012 and March 2022. Data on clinical characteristics, laboratory and radiological findings were collected, and their associations with the absence of detectable abscess lesions were analyzed., Results: In total, 393 participants were included. Abscess lesions were absent in 42.7% of the entire cohort and detectable in the remaining patients. No differences were identified in the malignancy, severity, or 30-day mortality between patients with and without detectable abscess lesions. Multivariate logistic regression analysis adjusted for age and the modified Charlson comorbidity score revealed that the immunosuppressive status (febrile neutropenia or corticosteroid use), C-reactive protein (CRP) level ≤9.8 mg/dL at onset, and the presence of gram-positive anaerobic rods (GPARs) were independently associated with AB unaccompanied by detectable abscess lesions [odds ratios (ORs) 3.24, 3.00, and 2.81, respectively; p < 0.05]., Conclusion: This study elucidated distinctive clinical and microbiological characteristics of AB unaccompanied by detectable abscess lesions, with relatively lower CRP elevation, immunosuppressive status, and GPARs as the causative anaerobes., (© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
42. Case report and literature review of refractory fungemia caused by Candida vulturna .
- Author
-
Setoguchi D, Iwanaga N, Ito Y, Hirayama T, Yoshida M, Takeda K, Ide S, Nagayoshi Y, Kondo A, Tashiro M, Takazono T, Kosai K, Izumikawa K, Yanagihara K, and Mukae H
- Abstract
Candida vulturna is a recently discovered and not widely documented ascomycetous yeast phylogenetically related to the outbreak-causing and multidrug-resistant Candida auris . A middle-aged Japanese man with no discernible immunodeficiency was admitted to hospital with ileal diverticulitis. Following laparoscopic right hemicolectomy against abscess formation on postoperative day (POD) 7, continuous fungemia occurred due to Candida haemulonii, identified using a conventional method by confirming the biochemical phenotype. Micafungin was initiated; however, the fungus was persistently isolated from blood cultures. Eventually, the antifungal agent was changed to a combination of liposomal amphotericin B (L-AMB) and caspofungin (CPFG), which cleared the infection, and no pathogens were detected in the blood cultures on POD 31. Contrast-enhanced computed tomography showed septic emboli in the lungs and spleen; however, no evidence of vasculitis was observed. Moreover, sequential echocardiography did not reveal any signs of infectious endocarditis. Finally, CPFG and L-AMB were administered to the patient for 7 and 9 weeks, respectively, during which the patient's symptoms did not relapse. The strain was later genetically identified as C. vulturna . This case report illustrates a clinical presentation of C. vulturna and provides the diagnostic approach and treatment methods for this pathogen., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
43. Nationwide survey in Japan of the causative diseases of bloody sputum and hemoptysis in departments of respiratory medicine at university hospitals and core hospitals.
- Author
-
Fujii H, Hara Y, Obase Y, Haranaga S, Takahashi H, Shinkai M, Terada J, Ikari J, Katsura H, Yamamoto K, Suzuki T, Tagaya E, Mukae H, and Kaneko T
- Subjects
- Male, Female, Humans, Aged, Young Adult, Adult, Middle Aged, Aged, 80 and over, Hemoptysis epidemiology, Hemoptysis etiology, Sputum microbiology, Japan epidemiology, Hospitals, University, Retrospective Studies, Tomography, X-Ray Computed, Pulmonary Medicine, Bronchiectasis epidemiology, Bronchiectasis complications, Lung Neoplasms complications, Lung Neoplasms epidemiology
- Abstract
Background: The Guidelines for the Management of Cough and Sputum (2019) of the Japanese Respiratory Society (JRS) were the first internationally published guidelines for the management of sputum. However, the data used to determine the causative diseases of bloody sputum and hemoptysis in these guidelines were not obtained in Japan., Methods: A retrospective analysis was performed using the clinical information of patients with bloody sputum or hemoptysis who visited the department of respiratory medicine at a university or core hospital in Japan., Results: Included in the study were 556 patients (median age, 73 years; age range, 21-98 years; 302 males (54.3%)). The main causative diseases were bronchiectasis (102 patients (18.3%)), lung cancer (97 patients (17.4%)), and non-tuberculous mycobacterial disease (89 patients (16%)). Sex and age differences were observed in the frequency of causative diseases of bloody sputum and hemoptysis. The most common cause was lung cancer in males (26%), bronchiectasis in females (29%), lung cancer in patients aged <65 years (19%), and bronchiectasis in those aged >65 years (20%)., Conclusions: The present study is the first to investigate the causative diseases of bloody sputum and hemoptysis using data obtained in Japan. When investigating the causative diseases of bloody sputum and hemoptysis, it is important to take the sex and age of the patients into account., Competing Interests: Declaration of competing interest KT received Grants-in-Aid for Scientific Research from Ministry of Health, Labour and Welfare (Nos. 20K08545). The other authors have no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Risk factor of non-tuberculous Mycobacterium infection in patients with rheumatoid arthritis and other autoimmune diseases receiving biologic agents: A multicenter retrospective study.
- Author
-
Ashizawa H, Takazono T, Kawashiri SY, Nakada N, Ito Y, Ashizawa N, Hirayama T, Yoshida M, Takeda K, Iwanaga N, Takemoto S, Ide S, Mihara T, Tomari S, Sakamoto N, Obase Y, Izumikawa K, Yanagihara K, Kawakami A, and Mukae H
- Subjects
- Humans, Retrospective Studies, Mycobacterium avium Complex, Nontuberculous Mycobacteria, Biological Factors therapeutic use, Risk Factors, Adrenal Cortex Hormones therapeutic use, Mycobacterium Infections, Nontuberculous drug therapy, Mycobacterium Infections, Nontuberculous epidemiology, Mycobacterium Infections, Nontuberculous complications, Arthritis, Rheumatoid complications, Arthritis, Rheumatoid drug therapy, Mycobacterium avium-intracellulare Infection epidemiology, Biological Products adverse effects
- Abstract
Background: Evidence regarding the association of the usage of biologic agents (Etanercept, Tocilizumab, adalimumab and so on), such as anti-tumor necrosis factor α, with the incidence and risk factors of non-tuberculous Mycobacteria (NTM) infection is limited. Therefore, this study aimed to investigate the incidence and risk factors of NTM and their associations with biologic agents' usage, and also investigated the potential of Mycobacterium avium complex (MAC) antibodies as a predictor of NTM infection development., Methods: This retrospective study included 672 patients with autoimmune diseases from four hospitals in Nagasaki, Japan, from January 1, 2011, to June 30, 2019, who fulfilled the inclusion criteria., Results: Of the 672 patients, 9 (1.3%) developed complicated NTM infection, including two with disseminated infection, after the introduction of biologic agents. Of the nine patients, two died due to NTM infection but none tested positive for MAC antibodies prior to initiation of biologic agents. The mortality rate was higher in patients complicated with NTM than without NTM (22.2% vs 2.6%, P = 0.024). The corticosteroids dosage at the time of initiating the biologic agents was significantly higher in the NTM group than in the non-NTM group (median, 17 mg vs 3 mg, P = 0.0038)., Conclusion: In the patients undergoing therapy with biologic agents, although NTM complication was rare, it could be fatal. In particular, for patients on a relatively high dose corticosteroids, careful observation is essential for identifying NTM complication, even if the MAC antibody test is negative., Competing Interests: Declaration of competing interest The authors have no conflicts of interest., (Copyright © 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
45. Renal tubular necrosis associated with anagrelide administration: a case report.
- Author
-
Sawase A, Kitamura M, Morimoto M, Fukuda H, Uramatsu T, Katafuchi E, Yamashita H, Nakayama T, Mukae H, and Nishino T
- Abstract
A 62-year-old female patient with essential thrombocythemia experienced rapid renal dysfunction and was subsequently referred to our hospital. Further investigations did not reveal any significant abnormalities except for a slight increase in urinary β2-microglobulin levels. A renal biopsy was performed to investigate the cause of her renal dysfunction, revealing acute tubular necrosis, interstitial edema, and arteriosclerosis. No significant glomerular lesions were observed. Immunofluorescence staining and electron microscopy showed no abnormalities. She had been using anagrelide for 4 years, and her dosage was increased from 2.0 to 3.0 mg/day 10 months before her initial admission. Her renal function began to deteriorate 2 months after the anagrelide dosage increase. Although 0.625 mg of bisoprolol was initiated for tachycardia 3 months after the anagrelide dosage adjustment, we suspected that the acute tubular necrosis was associated with anagrelide administration. After transitioning from anagrelide to hydroxyurea and discontinuing bisoprolol, her renal function improved. This case suggests the importance of considering anagrelide as a potential cause of renal dysfunction in patients using this medication. Therefore, renal biopsy, combined with a comprehensive medical history, is crucial for evaluating the etiology of renal injury in such cases., (© 2024. The Author(s), under exclusive licence to Japanese Society of Nephrology.)
- Published
- 2024
- Full Text
- View/download PDF
46. Dapagliflozin-induced drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Followed By Acute Interstitial Nephritis (AIN): A Case Report.
- Author
-
Tsuyuki T, Torigoe K, Shimizu M, Taira H, Sakamoto R, Abe S, Kuwatsuka S, Muta K, Mukae H, and Nishino T
- Abstract
A 78-year-old male was admitted to the hospital with acute renal failure and generalized erythema after starting dapagliflozin 10 mg/day for chronic kidney disease (CKD). A skin biopsy revealed superficial perivascular dermatitis with eosinophils. A renal biopsy revealed lymphocytic and eosinophilic infiltration of the interstitium, and focal tubulitis. The patient was diagnosed with a dapagliflozin-induced drug reaction with eosinophilia and systemic symptoms (DRESS), followed by acute interstitial nephritis (AIN), and prednisolone therapy was therefore initiated. The patient's renal function improved, and erythema disappeared. To our knowledge, this is the first report of DRESS caused by dapagliflozin, and the patient was successfully treated with prednisolone.
- Published
- 2024
- Full Text
- View/download PDF
47. Human Vγ9Vδ2 T cells exhibit antifungal activity against Aspergillus fumigatus and other filamentous fungi.
- Author
-
Koga S, Takazono T, Namie H, Okuno D, Ito Y, Nakada N, Hirayama T, Takeda K, Ide S, Iwanaga N, Tashiro M, Sakamoto N, Watanabe A, Izumikawa K, Yanagihara K, Tanaka Y, and Mukae H
- Subjects
- Humans, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Aspergillus fumigatus, Fungi, Aspergillus, Mucormycosis drug therapy, Aspergillosis drug therapy, Aspergillosis microbiology
- Abstract
Invasive aspergillosis (IA) and mucormycosis are life-threatening diseases, especially among immunocompromised patients. Drug-resistant Aspergillus fumigatus strains have been isolated worldwide, which can pose a serious clinical problem. As IA mainly occurs in patients with compromised immune systems, the ideal therapeutic approach should aim to bolster the immune system. In this study, we focused on Vγ9Vδ2 T cells that exhibit immune effector functions and examined the possibility of harnessing this unconventional T cell subset as a novel therapeutic modality for IA. A potent antifungal effect was observed when A. fumigatus ( Af293 ) hyphae were challenged by Vγ9Vδ2 T cells derived from peripheral blood. In addition, Vγ9Vδ2 T cells exhibited antifungal activity against hyphae of all Aspergillus spp., Cunninghamella bertholletiae , and Rhizopus microsporus but not against their conidia. Furthermore, Vγ9Vδ2 T cells also exhibited antifungal activity against azole-resistant A. fumigatus , indicating that Vγ9Vδ2 T cells could be used for treating drug-resistant A. fumigatus . The antifungal activity of Vγ9Vδ2 T cells depended on cell-to-cell contact with A. fumigatus hyphae, and degranulation characterized by CD107a mobilization seems essential for this activity against A. fumigatus . Vγ9Vδ2 T cells could be developed as a novel modality for treating IA or mucormycosis., Importance: Invasive aspergillosis (IA) and mucormycosis are often resistant to treatment with conventional antifungal agents and have a high mortality rate. Additionally, effective antifungal treatment is hindered by drug toxicity, given that both fungal and human cells are eukaryotic, and antifungal agents are also likely to act on human cells, resulting in adverse effects. Therefore, the development of novel therapeutic agents specifically targeting fungi is challenging. This study demonstrated the antifungal activity of Vγ9Vδ2 T cells against various Aspergillus spp. and several Mucorales in vitro and discussed the mechanism underlying their antifungal activity. We indicate that adoptive immunotherapy using Vγ9Vδ2 T cells may offer a new therapeutic approach to IA., Competing Interests: Y.T. is a co-inventor of JP2014-257451 (on the method for expanding γδ T cells using PTA) and JP2014-73475 (on the method for a nonradioactive cellular cytotoxicity assay). The other authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
48. Role of CD38 in anti-tumor immunity of small cell lung cancer.
- Author
-
Taniguchi H, Chavan SS, Chow A, Chan JM, Mukae H, Rudin CM, and Sen T
- Subjects
- Humans, B7-H1 Antigen, Cisplatin therapeutic use, Etoposide therapeutic use, Biomarkers, Tumor Microenvironment, Small Cell Lung Carcinoma drug therapy, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms pathology
- Abstract
Introduction: Immune checkpoint blockade (ICB) with or without chemotherapy has a very modest benefit in patients with small cell lung cancer (SCLC). SCLC tumors are characterized by high tumor mutation burden (TMB) and low PD-L1 expression. Therefore, TMB and PD-L1 do not serve as biomarkers of ICB response in SCLC. CD38, a transmembrane glycoprotein, mediates immunosuppression in non-small cell lung cancer (NSCLC). In this brief report, we highlight the potential role of CD38 as a probable biomarker of immunotherapy response in SCLC., Methods: We evaluated the role of CD38 as a determinant of tumor immune microenvironment in SCLC with bulk and single-cell transcriptomic analyses and protein assessments of clinical samples and preclinical models, including CD38 in vivo blockade., Results: In SCLC clinical samples, CD38 levels were significantly correlated with the gene expression of the immunosuppressive markers FOXP3 , PD-1 and CTLA-4 . CD38 expression was significantly enhanced after chemotherapy and ICB treatment in SCLC preclinical models and clinical samples. A combination of cisplatin/etoposide, ICB, and CD38 blockade delayed tumor growth compared to cisplatin/etoposide., Conclusion: Our study provides a preliminary but important direction toward exploring CD38 as a potential biomarker of ICB response and CD38 blockade as a combination strategy for chemo-immunotherapy in SCLC., Competing Interests: TS has grant funding from Jazz Pharmaceuticals. CR has consulted regarding oncology drug development with AbbVie, Amgen, Astra Zeneca, D2G, Daiichi Sankyo, Epizyme, Genentech/Roche, Ipsen, Jazz, Kowa, Lilly, Merck, and Syros. He serves on the scientific advisory boards of Auron, Bridge Medicines, DISCO, Earli, and Harpoon Therapeutics. JC has equity in Mirati Therapeutics and the provision of services from Sonata Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Taniguchi, Chavan, Chow, Chan, Mukae, Rudin and Sen.)
- Published
- 2024
- Full Text
- View/download PDF
49. Platypnoea-orthodeoxia syndrome in COVID-19 pneumonia patients: An observational study.
- Author
-
Hanada M, Ishimatsu Y, Sakamoto N, Ashizawa N, Yamanashi H, Sekino M, Izumikawa K, Mukae H, Ariyoshi K, Maeda T, Hara T, Sato S, and Kozu R
- Subjects
- Humans, Hypoxia etiology, Posture, Dyspnea etiology, Dyspnea therapy, Oxygen, Platypnea Orthodeoxia Syndrome, COVID-19 complications
- Abstract
This retrospective observational study aimed to assess the clinical characteristics of platypnea-orthodeoxia syndrome in patients with coronavirus disease 2019 (COVID-19) treated using mechanical ventilation or high-flow nasal canula. We analyzed 42 consecutive patients with COVID-19 from January 2020 to March 2022. The primary outcomes were the incidence of platypnea-orthodeoxia syndrome, the time with required long-term oxygen therapy, and short-term prognosis. Additionally, we examined the relationships between platypnea-orthodeoxia syndrome and COVID-19 severity, the time with long-term oxygen therapy, and short-term prognosis. Of the 42 included patients, 15 (35.7 %) had platypnea-orthodeoxia syndrome. Although mortality was not significantly different between both groups, the oxygen withdrawal rate in the platypnea-orthodeoxia syndrome group was significantly lower than that in the group without this syndrome. Clinical staff should be aware of the possibility of platypnea-orthodeoxia syndrome during positional changes in patients with COVID-19. Recognizing POS can improve early detection, countermeasures, and safety during physiotherapy., Competing Interests: Declaration of competing interest Tetsuya Hara reports lecture fees from Ono Pharmaceutical Co., Ltd., and grants from Ono Pharmaceutical Co., Ltd., Edwards Lifesciences Co., Ltd., and Asahi Kasei Pharma Co., Ltd., outside of the submitted work. Masatoshi Hanada, Yuji Ishimatsu, Noriho Sakamoto, Nobuyuki Ashizawa, Hirotomo Yamanashi, Motohiro Sekino, Koichi Izumikawa, Hiroshi Mukae, Koya Ariyoshi, Takahiro Maeda, Shuntaro Sato, and Ryo Kozu have no conflict of interest., (Copyright © 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
50. Efficacy and safety of macrolide therapy for adult asthma: A systematic review and meta-analysis.
- Author
-
Fukuda Y, Horita N, Aga M, Kashizaki F, Hara Y, Obase Y, Niimi A, Kaneko T, Mukae H, and Sagara H
- Subjects
- Humans, Adult, Treatment Outcome, Quality of Life, Randomized Controlled Trials as Topic, Female, Asthma drug therapy, Macrolides administration & dosage, Macrolides adverse effects, Macrolides therapeutic use
- Abstract
Background: The evidence for macrolide therapy in adult asthma is not properly established and remains controversial. We conducted a systematic review and meta-analysis to examine the efficacy and safety of macrolide therapy for adult asthma., Methods: We searched randomized controlled trials from MEDLINE via the PubMed, CENTRAL, and Ichushi Web databases. The primary outcome was asthma exacerbation. The secondary outcomes were serious adverse events (including mortality), asthma-related quality of life (symptom scales, Asthma Control Questionnaire, and Asthma Quality of Life Questionnaire), rescue medication (puffs/day), respiratory function (morning peak expiratory flow, evening peak flow, and forced expiratory volume in 1 s), bronchial hyperresponsiveness, and minimum oral corticosteroid dose. Of the 805 studies, we selected seven studies for the meta-analysis, which was conducted using a random-effects model., Systematic Review Registration: University Hospital Medical Information Network Clinical Trials Registry (UMIN000050824)., Results: No significant difference between macrolide and placebo for asthma exacerbations was observed (risk ratio 0.71, 95 % confidence interval [CI] 0.46-1.09; p = 0.12). Macrolide therapy for adult asthma showed a significant improvement in rescue medication with short-acting beta-agonists (mean difference -0.41, 95 % CI -0.78 to -0.04; p = 0.03). Macrolide therapy did not show more serious adverse events (odd ratio 0.61, 95 % CI 0.34-1.10; p = 0.10) than those with placebo. The other secondary outcomes were not significantly different between the macrolide and placebo groups., Conclusions: Macrolide therapy for adult asthma may be more effective than placebo and could be a treatment option., Competing Interests: Declaration of competing interest The authors have no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.